Please assess the completion status of the following clinical trial:

Trial Title: Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of advanced hematologic malignancy or other disease not curable by conventional chemotherapy, including any of the following:~  * Acute myeloid leukemia in complete remission (CR)\* (as defined by hematologic recovery, \< 5% blasts in the bone marrow by morphology, and a cellularity of \> 15%), meeting one of the following criteria:~    * In first complete remission (CR1) AND has high-risk disease as evidenced by any of the following:~      * Preceding myelodysplastic syndromes (MDS)~     * High-risk cytogenetics (e.g., monosomy 5 or 7, or as defined by referring institution treatment protocol)~     * Required \> 2 courses of therapy to obtain CR~     * Erythroblastic or megakaryocytic leukemia~   * In second CR (CR2) or beyond~ * Acute lymphoblastic leukemia in CR\* (as defined by hematologic recovery, \< 5% blasts in the bone marrow by morphology, and a cellularity of \> 15%), meeting one of the following criteria:~    * In CR1 AND has high-risk disease as evidenced by any of the following:~      * t(9;22), t(1;19), t(4;11), or other MLL rearrangements~     * Hyplodiploid~     * Required \> 1 course of therapy to obtain CR~   * Beyond CR2~ * Chronic myelogenous leukemia (CML)~    * All types are allowed (except refractory blast crisis CML)~   * Patients in chronic phase CML must have failed or been intolerant to prior imatinib mesylate (Gleevec) or other tyrosine kinase inhibitors~ * MDS~    * Any subtype allowed (including refractory anemia \[RA\])~   * Severe pancytopenia or complex cytogenetics~   * Blasts must be \< 5% (if blasts are ≥ 5%, pre-transplant induction therapy is required to reduce blast count to \< 5%)~ * Large cell lymphoma, Hodgkin lymphoma, or multiple myeloma, meeting one of the following criteria:~    * Chemotherapy-sensitive disease that has failed prior therapy~      * Patients with large cell lymphoma or Hodgkin lymphoma must not have progressive disease during salvage therapy (stable disease allowed provided it is non-bulky)~   * Ineligible for an autologous stem cell transplant~ * Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, or follicular lymphoma that has progressed after ≥ 2 prior therapies~    * Patients with bulky disease should be considered for debulking chemotherapy prior to transplant~   * Patients with refractory disease are eligible provided disease is non-bulky AND an estimated tumor doubling time is ≥ 1 month~ * Lymphoplasmacytic lymphoma, mantle cell lymphoma, or prolymphocytic leukemia~    * Chemotherapy-sensitive disease that was previously treated with initial therapy~      * Patients with mantle cell lymphoma must not have progressive disease during salvage therapy (stable disease allowed provided it is non-bulky)~ * Mycosis fungoides and Sezary syndrome~ * Bone marrow failure syndromes, except for Fanconi anemia~ * Myeloproliferative syndromes NOTE: \*Patients for whom adequate marrow/biopsy specimens can not be obtained to determine remission status by morphologic assessment must have fulfilled criteria of remission (\< 5% blasts by flow cytometry and recovery of peripheral blood counts with no circulating blasts)~* Ineligible for autologous stem cell transplant due to any of the following:~  * Prior autologous stem cell transplant~ * Inadequate autologous stem cell harvest~ * Inability to withstand a myeloablative preparative regimen~ * Clinically aggressive/high-risk disease~* No evidence of progressive disease by imaging modalities or biopsy (persistent PET scan activity allowed provided there are no CT scan changes indicating progression)~* Acute leukemia that is refractory, persistent, or relapsed (defined as \> 5% blasts in normocellular bone marrow) allowed provided patient was rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy~* Patients with stable disease are eligible provided the largest residual nodal mass is approximately \< 5 cm (largest residual mass must represent a 50% reduction and be approximately \< 7.5 cm for patients who have responded to prior therapy)~* No active CNS malignancy~* Umbilical cord blood (UCB) donor available~  * UCB graft matched at 4/6 HLA-A, -B, and -DRB1 antigens with the recipient~    * May include 0-2 antigen mismatches at the A, B, or DRB1 loci~   * Unit selection based on cryopreserved nucleated cell dose and HLA-A, -B, and -DRB1 using intermediate resolution A, B antigen and DRB1 allele typing~ * If 2 UCB units are required to reach the target cell dose, each unit must be a 3/6 HLA-A, -B, and -DRB1 antigen match to each other, as well as a 4/6 antigen match to the recipient~ * No 5-6/6 HLA-A, -B, and -DRB1 matched sibling donor available~PATIENT CHARACTERISTICS:~* Karnofsky performance status (PS) 60-100% OR Lansky PS 50-100%~* Creatinine ≤ 2.0 mg/dL (adults) OR creatinine clearance \> 40 mL/min (pediatrics)~  * Adult patients with a creatinine \> 1.2 mg/dL or a history of renal dysfunction must have an estimated creatinine clearance of \> 40 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* LVEF ≥ 35%~* DLCO \> 30% predicted~* No requirement for O_2~* No decompensated congestive heart failure~* No uncontrolled arrhythmia~* None of the following liver diseases or conditions:~  * Fulminant liver failure~ * Cirrhosis with evidence of portal hypertension or bridging fibrosis~ * Alcoholic hepatitis~ * Esophageal varices~ * History of bleeding esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time~ * Ascites related to portal hypertension~ * Bacterial or fungal abscess~ * Biliary obstruction~ * Chronic viral hepatitis with total serum bilirubin \> 3 mg/dL~ * Symptomatic biliary disease~* Recent mold infection (e.g., Aspergillus) allowed provided patient received ≥ 30 days of appropriate treatment AND infection is controlled and cleared by Infectious Disease~* No evidence of HIV infection or known HIV-positive serology~* No uncontrolled viral or bacterial infection~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 3 months since prior myeloablative stem cell transplantation

- Gender: ALL
- Minimum Age: None
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide/Fludarabine/TBI (Type: EXPERIMENTAL): Subjects with hematological malignancies with prior autologous transplant, \>2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months.~Refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy.
- Cyclophosphamide/Fludarabine/TBI/ATG (Type: EXPERIMENTAL): Subjects with hematological malignancies with prior autologous transplant \>12 mos or \<1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).